183 related articles for article (PubMed ID: 29104319)
1. Cytochrome
Stiborová M; Indra R; Frei E; Kopečková K; Schmeiser HH; Eckschlager T; Adam V; Heger Z; Arlt VM; Martínek V
Monatsh Chem; 2017; 148(11):1983-1991. PubMed ID: 29104319
[TBL] [Abstract][Full Text] [Related]
2. NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[
Stiborová M; Indra R; Moserová M; Šulc M; Hodek P; Frei E; Schmeiser HH; Arlt VM
Monatsh Chem; 2016; 147():847-855. PubMed ID: 27110038
[TBL] [Abstract][Full Text] [Related]
3. Application of hepatic cytochrome b
Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
Stiborová M; Indra R; Moserová M; Cerná V; Rupertová M; Martínek V; Eckschlager T; Kizek R; Frei E
Chem Res Toxicol; 2012 May; 25(5):1075-85. PubMed ID: 22390216
[TBL] [Abstract][Full Text] [Related]
5. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
6. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
[TBL] [Abstract][Full Text] [Related]
8. NADH:Cytochrome b5 Reductase and Cytochrome b5 Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene.
Stiborová M; Indra R; Moserová M; Frei E; Schmeiser HH; Kopka K; Phillips DH; Arlt VM
Chem Res Toxicol; 2016 Aug; 29(8):1325-34. PubMed ID: 27404282
[TBL] [Abstract][Full Text] [Related]
9. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
10. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
Inui H; Maeda A; Ohkawa H
Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.
Kotrbová V; Mrázová B; Moserová M; Martínek V; Hodek P; Hudeček J; Frei E; Stiborová M
Biochem Pharmacol; 2011 Sep; 82(6):669-80. PubMed ID: 21683692
[TBL] [Abstract][Full Text] [Related]
13. Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[
Stiborová M; Indra R; Moserová M; Bořek-Dohalská L; Hodek P; Frei E; Kopka K; Schmeiser HH; Arlt VM
Monatsh Chem; 2017; 148(11):1959-1969. PubMed ID: 29104317
[TBL] [Abstract][Full Text] [Related]
14. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes.
Yamazaki H; Nakano M; Imai Y; Ueng YF; Guengerich FP; Shimada T
Arch Biochem Biophys; 1996 Jan; 325(2):174-82. PubMed ID: 8561495
[TBL] [Abstract][Full Text] [Related]
15. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
[TBL] [Abstract][Full Text] [Related]
16. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract][Full Text] [Related]
18. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
[TBL] [Abstract][Full Text] [Related]
19. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
[TBL] [Abstract][Full Text] [Related]
20. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
